The total mass, copy number, and distribution of hormones in the human bloodstream Authors: Ron Sender, Tal Kedar, Yoav Navon, Moriya Raz, Shirley Bikel, Rina Hemi, Ron Milo, Shai Fuchs, Ines Alvarez-Garcia, Ines Alvarez-Garcia, Ines Alvarez-Garcia, Ines Alvarez-Garcia, Ines Alvarez-Garcia, Ines Alvarez-Garcia, Ines Alvarez-Garcia, Ines Alvarez-Garcia, Ines Alvarez-Garcia, Ines Alvarez-Garcia Published: 2026 ABSTRACT The human endocrine system orchestrates critical physiological processes, yet a systematic quantitative synthesis of clinically relevant circulating hormones has been lacking. Here, we present a comprehensive, integrative analysis of circulating human hormones, leveraging clinically validated reference intervals across major endocrine subsystems. We use clinically validated reference intervals that we further validate using published datasets. Our analysis reveals that the total mass of circulating hormones is approximately 40 ± 2 mg. We find that this mass in healthy young adults is dominated by Adiponectin and DHEAS, which constitute over 90% of both total hormone weight and copy number. We show there are on the order of a million hormone molecules per cell in the human body. Females have about half the number of circulating hormone molecules compared to males. Across 56 hormones with curated affinity data, free (receptor-available) concentration correlates with receptor binding affinity, with class-specific scaling. Bioavailability mechanisms segregate by chemical class, consistent with chemical structure constraining available buffering strategies. Together, these data provide a quantitative reference for the human endocrine system and highlight relationships linking receptor affinity, bioavailability, and chemical class. Introduction The endocrine system regulates energy balance and distributes nutritional energy across various levels of physiological activity and homeostasis. It governs critical functions including growth, metabolism, reproduction, and stress response through a network of circulating hormones [1, 2]. While comparing hormone concentrations within specific endocrine circuits (e.g., TSH and free T4) is common in clinical diagnostics and research, and cross-species comparisons of one or a few hormones have proven valuable in evolutionary studies [3, 4], a comprehensive, integrative analysis of circulating hormones has been lacking. Though several databases catalog messenger molecules [5–7], a quantitative comparison across hormones has not been performed. Here, we present a comprehensive, integrative, quantitative analysis of human hormone abundances, focusing on clinically assayed hormones with established reference intervals, assessing their relative abundances within a unified framework. Clinical reference ranges, first introduced as a concept in the 1960s [8, 9], represent an ongoing effort to acquire and analyze data from healthy subjects according to standardized guidelines [10–12]. As such, they provide insight into the physiology of human blood analytes. Typically, the reference interval encompasses the central 95% of a reference population, centered on the median [12] with some exceptions derived from physiological endpoints (e.g., fasting glucose) [13]. Using established clinical reference intervals, we compiled a database of 63 hormones, mostly routinely assayed in medical laboratories (with a minority primarily measured in research and specialty contexts), spanning the endocrine glands and hormone-secreting tissues. We then performed an integrated analysis of abundance patterns, validated our findings through examination of published cohorts, and extended our analysis to available data for the wider human hormonal repertoire. Results Two hormones comprise ≈90% of the circulating mass The total mass of hormones circulating in the blood of a healthy young adult is approximately 40 mg (≈41.5 mg in men and ≈39.5 mg in women). This mass is dominated by two hormones: adiponectin and dehydroepiandrosterone sulfate (DHEAS). Adiponectin, primarily produced by adipose tissue, contributes roughly 74% of total mass in men and 83% in women (≈31 mg in men, ≈33 mg in women). DHEAS, a sulfated reservoir form of an androgen precursor synthesized in the adrenal glands, differs between sexes: it comprises ≈20% of the total in men (≈8 mg) but only 11% in women (≈4 mg) (Fig 1, Fig A in S1 Appendix). The distribution of hormone mass in human blood is dominated by two hormones. Voronoi diagrams illustrating the distribution of the circulating hormones by mass in women (see Fig A in S1 Appendix for men). The area of each polygon is proportional to the relative mass of each hormone. Colors represent different endocrine systems or hormone types. The top 10 contributors are labeled with their names and percentage contributions. Adiponectin and DHEAS dominate the hormone mass in both sexes, together accounting for approximately 93% of the total. Total circulating hormone mass is approximately 40 mg in both women and men. Underlying data: S1 Data, sheet Hormone_abundance. Generated using the Proteomaps tool (http://bionic-vis.biologie.uni-greifswald.de/). Following these two dominant hormones, the liver-derived insulin-like growth factors, IGF-2 and IGF-1, are the next most abundant in both sexes. The remaining 59 clinically assayed hormones each contribute less than 0.5% to the total circulating hormone mass, collectively representing only 3%. The significant contributions of adipose tissue (through adiponectin) and liver (through IGFs) to the total circulating hormone mass highlight the important role of non-classical endocrine tissues in overall endocrine function (Fig B in S1 Appendix). While total mass provides insight into biosynthetic investment, the biological impact of hormones depends on their molecular interactions with receptors. Therefore, we next examined the number of circulating molecules for each hormone to understand their potential signaling capacity. Hormone molecule copy numbers show dominance of the adrenal cortex and sexual dimorphism Next, we evaluated the number of circulating molecules per hormone, which reflects the potential for receptor-mediated signaling. In a reference male, we estimate approximately ≈25 µmol in total, compared to 14 µmol in women. This is equivalent to ≈15 × 1018 and ≈8 × 1018 circulating hormone molecules in men and women respectively, showing that the female hormone molecule copy number is nearly half that of male (Fig 2 and Fig C in S1 Appendix). Given that the estimated number of cells in the male and female body is ≈3 × 1013 and ≈2 × 1013, respectively [14], we find that at any given moment, there are close to a million circulating hormone molecules per cell in the human body. The distribution of hormone molecule copy numbers in males and females. The distribution is represented by a Voronoi diagram, such that the area of each polygon is proportional to the fractional abundance of a given hormone. Juxtaposing male (left) and female (right), the area of the square is proportional to the total number of circulating molecules. In males, the total count of hormone molecules (≈25 μmol or ≈1.5 × 1019 molecules) is nearly double that in females (≈14 μmol or ≈8 × 1018 molecules). Underlying data: S1 Data, sheet Hormone_abundance. Generated using the Proteomaps tool (http://bionic-vis.biologie.uni-greifswald.de/). DHEAS, a sulfated isoform of the adrenal androgen precursor, dominates circulating hormones, accounting for 90% and 83% of total hormone molecules in males and females, respectively (Fig 2). Collectively, adrenocortical steroid hormones constitute approximately 90% of circulating hormone molecules in both sexes. Adiponectin shows sexual dimorphism: it comprises 8% of circulating hormone molecules in females, double its 4% contribution in males. Adiponectin’s molecular count contrasts with its overall dominance in total hormone mass, reflecting its high molecular weight. Circulating hormone abundance spans eight orders of magnitude We examined the distribution of hormone abundances across molecular weights and hormone types. Fig 3 illustrates the relationship between hormone molecular weight and circulating molecule copy numbers. Hormone molecular weights span three orders of magnitude and cluster strongly by hormone type: amine hormones and steroids (102–103 daltons), followed by peptide hormones (103–104 Da), and then glycoproteins (104–105 Da) (Fig D in S1 Appendix). Distribution of circulating hormones by molecular weight and abundance in females. Hormones are plotted by molecular weight (x-axis) and circulating abundance (y-axis). Colors represent secreting glands/tissues, while shapes indicate hormone types (e.g., peptide, steroid). Diagonal iso-mass lines show total circulating mass in grams (product of molecular weight and abundance). For gonadotropins and sex hormones, median copy numbers are based on reference intervals from the phase of the menstrual cycle when levels are lowest per hormone. Corresponding distribution for males is presented in Fig E in S1 Appendix. Underlying data: S1 Data, sheet Hormone_abundance. Code: Zenodo DOI https://doi.org/10.5281/zenodo.20110628. Circulating hormone molecule counts span a hundred million-fold range, and do not manifest any clear pattern. Because total circulating mass per hormone is the product of molecular weight and molar abundance, diagonal iso-mass lines in Fig 3 reveal hormones with similar total circulating masses. Classification by molecular weight and tissue origin does not, on its own, explain hormone abundance. To identify determinants of hormone abundance, we examined receptor binding affinity, bioavailability, and elimination half-life. Circulating hormone abundance partially scales with receptor binding affinity in a hormone class-dependent manner To investigate potential determinants of the widely varying hormone circulating abundance, we assembled binding affinity data for hormone-receptor pairs and examined whether concentration relates to receptor binding affinity, and whether incorporating free fraction, half-life, or hormone class improves explanatory power. We mined public databases and primary literature to compile equilibrium dissociation constants (Kd) for 56 hormones and their primary cognate receptor, prioritizing measurements performed under physiological conditions when available (S2 Data, sheet ‘Kd’). In parallel, we curated two additional datasets: receptor-available fractions (accounting for protein binding and, where applicable, reservoir/activation steps) and circulating half-lives (S2 Data, sheets ‘Bioavailability’ and ‘Half_life’). Linear regression in log–log space revealed a significant relationship between circulating hormone concentration and receptor Kd (R2 = 0.29, p < 0.001) (Fig H in S1 Appendix). Because receptor engagement depends on the free (unbound) ligand concentration, we repeated the analysis using estimated free concentrations; model performance increased slightly (R2 = 0.31), and we retained free concentrations for downstream analyses as a physiologically interpretable estimate of the ligand pool available for receptor interaction. Adding circulating half-life as a covariate did not improve model performance (adjusted R2: 0.293 → 0.264; AIC: 162.1 → 168.5), indicating no incremental explanatory power from half-life in this linear framework. Allowing both intercepts and slopes to vary by hormone class (amines, peptides, glycoproteins, steroids) significantly improved model fit (ΔR2 = 0.16, F(7,48) = 5.89, p = 5.7 × 10−5), indicating that concentration–affinity scaling is structured by the hormones’ chemical class. The estimated power-law exponents vary across classes, ranging from β = 0.17 (peptides) to β = 1.10 (amines), with intermediate values for glycoproteins (β = 0.52) and steroids (β = 0.70) (Fig 4C–4F). Individual classes contain too few hormones to support well-powered tests of within-class slopes. At the level of class means, the four groups occupy distinct positions along the concentration–Kd relationship (R2 = 0.85, n = 4 classes, p = 0.078; Fig 4B). Receptor affinity scales with circulating hormone availability, with class-dependent scaling. (A) Log–log relationship between receptor binding affinity (Kd, M) and free (receptor-accessible) circulating hormone count [moles] across hormone–receptor pairs (linear regression fit ± 95% CI; R2 = 0.306, p = 9.9 × 10−6). (B) Between-class (“ecological”) relationship using class means (n = 4 classes; shown as an exploratory summary; R2 = 0.85, p = 0.078). (C–F) Within-class log–log relationships for steroids (C), amines (D), peptides (E), and glycoproteins (F), with linear regression fits and 95% confidence bands. The class-stratified model (R2 = 0.46, F(7, 48) = 5.89, p = 5.7 × 10−5) significantly improves fit over the single-slope model, supporting class-dependent scaling. Individual class slopes differ numerically but not significantly from the reference class (amines): steroids p = 0.45, peptides p = 0.08, glycoproteins p = 0.19. Underlying data: S2 Data, sheets Master_table and Kd. Code: Zenodo DOI https://doi.org/10.5281/zenodo.20110628. Mechanisms of sequestration vary by hormone class Receptor-available fraction and circulating half-life contributed little additional explanatory power for hormone abundance beyond affinity-based models (ΔR2 < 0.01), yet their systematic curation revealed strong class-structured organization. We classified four dominant strategies shaping receptor availability: negligible/no sequestration (receptor-available fraction ≈ 1), conjugation, post-translational processing/activation steps, and carrier binding (reversible sequestration, mostly by protein carriers). These strategies segregated by hormone chemical class (χ2 = 60.31, df = 9, p < 0.001; Cramér’s V = 0.61; Fig 5A and Fig I in S1 Appendix): glycoproteins showed minimal sequestration (7/7), steroids showed carrier binding (16/16), amines partitioned between conjugation and carrier binding (3/7 and 4/7, respectively), and peptides exhibited greater diversity. Consistent with this mechanistic segregation, receptor-available fraction differed significantly across hormone classes (one-way ANOVA: F3,51 = 39.68, p < 0.001; Fig 5A), with steroids displaying markedly lower receptor-available fractions than glycoproteins and peptides (Tukey HSD post-hoc: p < 0.001 for both comparisons). Among sequestered hormones, receptor-available fraction was inversely associated with circulating half-life (R2 = 0.40, slope = −0.54, p < 0.001, n = 32; Fig 5B). Together, these analyses suggest a structured relationship in which chemical class constrains feasible sequestration mechanisms, mechanism choice shapes receptor-available fraction, and stronger sequestration is associated with longer circulating residence times. Sequestration and bioavailability vary by hormone type and correlate with half-life. (A) Receptor-available fraction by hormone class. Boxes show median and IQR; whiskers extend to 1.5 × IQR; points are individual hormones. Fill patterns denote sequestration mechanism. Receptor availability differs significantly across classes (one-way ANOVA, F = 39.68, p < 0.001) and associates with sequestration mechanism (χ2 = 60.31, p < 0.001, Cramér’s V = 0.61). (B) Receptor-available fraction vs. half-life (log10-scaled axes). Among sequestered hormones (filled symbols, n = 32), availability decreases with increasing half-life (R2 = 0.40, slope = −0.54, p < 0.001; regression line shown). Non-sequestered hormones (open symbols, n = 23) were excluded from the fit. Underlying data: S2 Data, sheets Master_table, Bioavailability, and Half_life. Code: Zenodo DOI https://doi.org/10.5281/zenodo.20110628. Sex-specific differences in hormone abundance In our analysis, we used reference intervals available for both young adult females and males. The difference between males and females emanates from two factors—serum volume, whereby female serum volume is 2.4 L while male serum volume is 3 L [15]; and differences in median concentrations. For hormones with fluctuating levels, such as those varying throughout the menstrual cycle, we adhered to using the reference values corresponding to the stage where the hormone level is at its minimum. However, even substantial menstrual-related fluctuations, such as a 13-fold increase in LH during ovulation, exert a negligible influence on the total hormone mass and count. Out of the 63 hormones and hormone isoforms in our cohort, 31 have the same reference intervals in males and females. The main differences, as could be expected, are in sex hormones and adipokines, the latter corresponds to the higher percent body fat mass in females. These differences are most pronounced in the two main contributors to hormone mass and count: adiponectin levels are generally higher in females due to greater body fat percentage, while DHEAS levels are typically higher in males, reflecting its role as an androgen precursor. Validation and comprehensive analysis of hormone mass estimation Our hormone abundance analysis is based on using the geometric mean of reference interval bounds as a proxy for the median in a reference young adult population. To estimate the error in this approach, we examined the published studies reporting hormone levels in healthy young adult cohorts. We focused on adiponectin and DHEAS, which comprise ≈93% of the total hormone mass and copy number. Analysis of the seven published studies on hormone levels in young adults revealed literature-derived median expressions (Table 1 and Table B in S1 Appendix). From these, we calculated total circulating masses of 26 mg (men) and 33 mg (women) for adiponectin, and 10 mg (men) and 5 mg (women) for DHEAS. The sum of these two hormones is therefore 36 mg in men and 38 mg in women. In comparison, our main analysis yielded 39 mg in men and 37 mg in women for this sum. This indicates an overestimation of up to 11% for men and 3% for women in our approach. Given that all other hormones combined contribute less than 3 mg to the total, further analysis of these minor contributors is unlikely to significantly alter this error estimation. 10.1371/journal.pbio.3003864.t001Table 1Literature-derived estimation of median and distribution of adiponectin and DHEAS concentrations in young adults.Median [µg/ml]Total variation [µg/ml]hormonesexestimateCI95%50%90%AdiponectinF13.713.2–14.210.2–18.56.6–28.2AdiponectinM8.58.1–8.86.1–11.63.9–18.3DHEASF1.91.8–2.41.5–2.91.1–4.7DHEASM3.23.0–3.52.4–4.21.6–5.9This table presents the literature-derived median estimates and total variation for adiponectin and DHEAS concentrations stratified by sex. Median estimates are accompanied by their 95% confidence intervals (CI95%). Total variation is represented by interquartile ranges covering 50, and the 90% of the population, respectively. The data were obtained from a systematic review of studies involving individuals aged 20–30 years, with bootstrapping methods applied to estimate central tendency and variability. Underlying data: Table C in S1 Appendix. Literature-derived estimation of median and distribution of adiponectin and DHEAS concentrations in young adults. This table presents the literature-derived median estimates and total variation for adiponectin and DHEAS concentrations stratified by sex. Median estimates are accompanied by their 95% confidence intervals (CI95%). Total variation is represented by interquartile ranges covering 50, and the 90% of the population, respectively. The data were obtained from a systematic review of studies involving individuals aged 20–30 years, with bootstrapping methods applied to estimate central tendency and variability. Underlying data: Table C in S1 Appendix. To quantify the coverage of our primary analysis, we conducted a comprehensive screening of 7,996 candidate entries from UniProt and HORDB databases, and in the seminal textbooks of pediatric and adult clinical endocrinology [5, 6, 16–18]. Our evaluation of an additional 124 endocrine molecules beyond the primary cohort revealed they contribute approximately 2.2 mg to the total circulating mass, representing a minor (~6%) potential underestimation. This multi-tiered validation, comparing our clinical reference-based estimates with published cohorts for high-abundance markers like adiponectin and DHEAS, provides a total hormone mass of 41.5 ± 1.5 mg for men and 39.5 ± 1.5 mg for women. We conclude that our error estimation based on the geometric mean of reference interval boundaries is ≈5% of the total circulating hormone mass in the reference human. This error margin affirms that our main analysis captures the vast majority of circulating hormone abundance. Biological variation context For 25 hormones with available entries in the EFLM Biological Variation Database [19], between-subject variability (CVg) generally exceeded within-subject variability (CVi) (median CVg ≈ 0.32; median CVi ≈ 0.17; Table D in S1 Appendix). Variability did not segregate by biochemical class, with both low- and high-variability hormones present in each class (Table D in S1 Appendix). The lowest variability was observed for thyroid hormones (T3 total: CVg ≈ 0.12, CVi ≈ 0.06), whereas higher variability was observed for prolactin (CVg ≈ 0.64, CVi ≈ 0.45) (Table D in S1 Appendix). Hormones with pronounced circadian or pulsatile dynamics are represented here by reference-interval–anchored summary concentrations rather than time-resolved profiles (see Methods). Discussion We assembled a quantitative overview of circulating hormone abundance in humans by combining clinically defined reference intervals with published datasets and applying a multi-step validation procedure. Using this approach, we estimate that the total blood hormone mass is 41.5 ± 1.5 mg for men and 39.5 ± 1.5 mg for women with an estimation error under 5%. This framework brings hormone families that are typically discussed separately onto a common scale, allowing direct comparisons of their circulating pools in units of both mass and molarity. Our account highlights an eight orders-of-magnitude spread in circulating hormone molecule count, framing the question of what constraints shape the landscape of hormone abundance. Recent work has suggested that endocrine gland size scales with the size of target tissues [20] raising the possibility that production capacity and tissue mass could influence circulating pool sizes. Consistent with this idea, large-mass tissues such as adipose and liver contribute substantially to the circulating mass of some hormones in our estimates, including adiponectin and IGFs, respectively. However, tissue mass alone is not sufficient to systematically account for the overall abundance patterns across hormones. Moreover, the aggregate mass of circulating hormones (~40 mg) is negligible relative to typical daily whole-body biomass turnover (~100 g) [21], suggesting that global biomass supply is unlikely to be limiting. These considerations motivate asking whether receptor affinity and class-linked buffering mechanisms offer a clearer framework than production capacity alone. We then examined the relationship between hormone abundance and receptor binding affinity (Kd) across 56 hormones with available binding data. Total circulating concentrations showed a positive correlation with Kd (R2 = 0.29, Fig H in S1 Appendix): higher-abundance hormones generally bind their cognate receptors with lower affinity. These patterns are compatible with concentration-affinity matching principles analogous to those in metabolic networks [22], where substrate concentrations are maintained high enough to keep enzyme binding sites occupied. Accounting for bioavailability to estimate free (receptor-accessible) concentrations improved the correlation with binding affinity modestly (R2 = 0.31 versus 0.29, ΔR2 = 0.02, p = 9.9 × 10−6, Fig 4A). This modest improvement is consistent with established observations that when tissue uptake is elimination-limited, intracellular hormone concentrations are proportional to free serum concentrations regardless of uptake mechanism [23]; the limited divergence between total and free predictive power reflects moderate binding fractions (10%–50%) for most hormones in our dataset. The remaining variance likely reflects unmeasured factors such as receptor abundance, receptor subtype diversity, cofactor requirements, tissue-specific expression, temporal dynamics, and blood-tissue compartmentalization. We focused on endocrine ligands with standardized clinical measurement in blood, spanning steroids, amines, peptides, and glycoproteins. Locally acting mediators (eicosanoids, gaseous messengers) and predominantly immune signaling molecules (many cytokines), and growth factors are not included. The included classes differ in size, solubility, carrier binding, and clearance, properties that are expected to influence both circulating pool size and receptor-accessible exposure [17, 18]. We next asked whether the concentration–affinity relationship follows a single rule across hormones or instead differs by chemical class. The class separation in Fig 4 is consistent with class-linked constraints, such as size, solubility, carrier binding, and clearance, which affect both circulating pool size and receptor-accessible exposure. This interpretation is reinforced by bioavailability patterns (Fig 5 and Fig I in S1 Appendix): sequestration mechanisms segregate sharply by class, producing systematically different free fractions, and among sequestered hormones stronger buffering is associated with longer circulating residence times (Fig 5B). Together, these findings suggest that chemical class is an organizing axis because it constrains the buffering and clearance strategies available to a hormone, which in turn shapes receptor-accessible exposure. To examine whether high-abundance hormones share common features, we defined a “top set” as the union of the top five hormones ranked by total mass and by molarity, evaluated separately in each sex, which yields a stable set of seven hormones that recurs across both measures and sexes (with rank order varying). These seven span an array of physiological domains: energy metabolism and insulin sensitization (adiponectin), growth and tissue maintenance (IGF-1, IGF-2), the stress response (cortisol), androgen precursor biology (DHEAS), thyroid hormone regulation (T4), and calcium and bone homeostasis (calcidiol), yet they share common circulation-level features. Six of the seven are extensively carrier-protein bound; three of these, T4, calcidiol, and DHEAS, are additionally upstream precursors requiring enzymatic activation to more potent forms. T4 and calcidiol engage the same receptors as their active products but with 10- to 30-fold and ~1,000-fold lower affinity, respectively [24–26]. DHEAS is not an androgen-receptor ligand, but has been reported as a candidate sigma-1 agonist in pharmacological assays; accordingly, we map DHEAS to sigma-1 as an operational assignment [27, 28], and validate through sensitivity analysis (methods). Last, adiponectin employs a distinct buffering mechanism: its insulin-sensitizing and anti-inflammatory activity depends on assembly into high-molecular-weight oligomers rather than release from carrier protein [29]. Taken together, these seven illustrate a common theme: large circulating pools are usually maintained by mechanisms that decouple total abundance from immediate receptor exposure. Adiponectin is a case in point: total mass is the largest of any circulating hormone, yet it barely figures in routine clinical practice. Conversely, low-abundance hormones such as insulin and GnRH exert outsized physiological effects through high receptor affinity and signal amplification. Abundance therefore reflects circulation-level buffering architecture, not physiological importance. While total hormone mass is similar between sexes, we observed important sex-specific differences in hormone count. Men have nearly double the number of circulating hormone molecules compared to women, primarily due to variations in DHEAS levels. The X-linked Steroid sulfatase enzyme, which negatively controls DHEAS abundance, escapes X-inactivation, leading to 2-fold higher expression and activity in females [30, 31], contributing to these differences. While menstrual cycle stages minimally impact overall hormone mass due to the relatively low abundance of gonadotropins and estrogen, pregnancy profoundly alters the female hormonal landscape, with human placental lactogen alone reaching over 20 mg in the third trimester (50% of total hormone mass in non-pregnant women), attesting to the placenta as a high-biomass hormonally active organ [32, 33]. This study quantifies clinically assayed circulating hormones in adults, rather than attempting an exhaustive census of endocrine signaling molecules. To contextualize how representative this quantified subset is, we assembled a broader catalogue of endogenous hormones using a conventional endocrinology scope and then asked what fraction is covered by standardized clinical measurement. Under this definition, the quantified subset comprises roughly one-third of catalogued hormones yet captures ~95% of total circulating hormone mass, providing a substantial sample for evaluating whether abundance exhibits reproducible structure. Extending the same quantitative framework to the remaining catalogue is an important next step, but will likely be noisier in the near term, since many non-clinically assayed hormones are less well characterized with respect to circulating ranges, binding, and clearance and are supported by a thinner literature base. Several limitations of our analysis should be noted. Reliance on reference intervals from a primary resource necessarily neglects variance across laboratories, assay platforms, and measurement matrices (serum versus plasma; immunoassay versus mass spectrometry). Moreover, the notion of a single “reference healthy human” elides systematic population differences. For example, adiponectin levels have been reported to be 30%−40% lower in self-reported African-Americans compared to self-reported White or Hispanic participants [34, 35], underscoring the need for population-specific analyses. Within individuals, our approach also sets aside the temporal pattern of many hormones (circadian rhythms, pulsatility, seasonality, and state dependence). These sources of heterogeneity are likely to contribute primarily to residual scatter in cross-hormone comparisons; however, because the log–log relationships analyzed here span multiple orders of magnitude, moderate shifts in any single reference interval are unlikely to account for the qualitative scaling patterns we report. Placing diverse hormone families on a common quantitative scale reveals reproducible structure. Circulating concentration correlates modestly with receptor affinity, scaling behavior differs across chemical classes, and bioavailability mechanisms segregate by class. These patterns are consistent with concentration–affinity matching ideas, with bioavailability providing a tunable layer shaped by constraints on solubility, clearance, and receptor access. The relationships remain correlational and explain only part of the variance, but they provide a quantitative baseline that highlights regularities and outliers and motivates testable hypotheses about endocrine organization. Future work can link these abundance patterns to receptor abundance and tissue distribution, carrier binding stoichiometry, and time-resolved secretion and clearance. Broadening coverage to the full annotated hormone list, across the pediatric and aging human, special physiological states such as pregnancy and the postprandial period, and pathologies from obesity to infectious disease, would provide stronger tests of generality and refine the inferred scaling relationships. Methods Data sources and reference values We obtained clinical reference values primarily from the Mayo Clinic’s public test catalog, which compiles ranges used in routine clinical practice and cites Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics as a key reference [13]. When Mayo did not provide a reference interval, or when additional context was needed (e.g., manufacturer insert, platform-specific interval, or population qualifier), we annotated alternative sources alongside the extracted interval (Table A in S1 Appendix). Reference human model and reference conditions All calculations use a reference young–adult model. Unless otherwise noted, the reference male and female were assumed to be 73 and 60 kg, respectively [15]. Where an age parameter was required, we used 25 years as a modeling assumption. Concentrations were interpreted as serum values measured under standard clinical sampling conditions (healthy, non-pregnant, and typically morning/fasting). For hormones with cyclic physiology (e.g., gonadotropins and ovarian steroids), we used the phase of the menstrual cycle associated with the lowest values, consistent with the aim of estimating baseline circulating pools. Serum volumes used to convert concentrations to circulating pools were 3.0 L for males and 2.4 L for females, based on prior whole-body blood and serum volume estimates [15]. Deriving representative concentrations from reference intervals Representative concentrations were derived from reference intervals by taking the geometric mean of the lower and upper bounds. This choice reflects the approximate lognormal distribution of many laboratory analytes, including hormones [8, 36]. When the lower bound of a reference interval was reported as 0, we treated the value as left-censored and substituted half the assay limit of detection (LOD/2) as the lower bound, a standard convention for lognormal censored data [37]. LOD values were compiled from assay documentation and are provided in S1 Data (sheet: LOD). Calculation of total circulating mass, molarity, and molecule counts Reference concentrations were converted to mass concentration (pg/ml) and multiplied by sex-specific serum volume to obtain the total circulating mass per hormone. Molar abundance was obtained by dividing mass by molecular weight and converting to molar units; and circulating molecule counts were obtained by multiplying moles by Avogadro’s number. For hormones that circulate bound to carrier proteins, we used the molecular weight of the hormone itself (not the protein–hormone complex) for molar conversions to maintain comparability across mechanisms of bioavailability. The vast majority of clinical hormone assays use serum as the measurement matrix; a small number of hormones (ACTH, PTH, and renin in some assays) are preferentially measured in plasma due to specific stability requirements, and we used the matrix specified in the clinical reference source for each hormone. Unit conversions For hormones reported in activity concentration units (IU/L, mIU/L), we converted to mass concentration units using ratios derived from National Institute for Biological Standards and Control (NIBSC) reagent data sheets (S1 Data, sheet: AU_conversion). Molecular weights were retrieved from the PubChem database. For protein-bound hormones, we used the weight of the unbound molecule. For hormones assayed as subunits or complexes (e.g., glycoprotein hormones), we used the molecular weight of the intact circulating hormone for molar conversions. Hormone–receptor binding affinity (Kd) curation Receptor binding affinities (Kd, Ki, or IC50) were curated for each hormone’s known receptor(s) through two independent searches. The IUPHAR/BPS Guide to Pharmacology database (GtoPDB; accessed 10 June 2025) was queried for endogenous hormone–receptor interactions and associated affinity values. An independent agentic literature search was performed using GPT-4 (OpenAI) to retrieve candidate affinity data and supporting PubMed identifiers for each hormone. All candidate entries from both sources were manually reviewed: each retrieved PMID was individually accessed and the reported affinity value, assay type, and molecular context were verified against the original publication. Only values confirmed in primary sources were included in S2 Data. The affinity table in S2 Data records all known receptors for each hormone but assigns one as the primary receptor used in downstream calculations. Assignment was based on canonical target identity (e.g., cortisol and the glucocorticoid receptor) or, when no single canonical target was evident, on highest receptor abundance in the canonical target tissue. Where neither criterion was sufficient, selection rationale was specified in the comments field. Primary receptor assignments were reviewed by the corresponding author (S.F.) and locked prior to statistical analysis (author R.S). Values were recorded as equilibrium dissociation constants (Kd) when available. When Kd was not reported, we captured the closest equilibrium binding proxy provided by the source (e.g., Ki from competition binding) and recorded the affinity type explicitly. Reported affinities were converted to molar units. For each hormone–receptor pair, we preferentially selected measurements on human receptors (native or recombinant) under near-physiological conditions. When multiple values were available, we favored full-length receptor assays closest to the relevant biological context. If human data were unavailable, we accepted measurements from closely related mammalian species, with species and assay context documented in S2 Data. In cases where Ki values were derived from competition assays, we retained the reported Ki and, when the source provided sufficient information, documented the conversion assumptions used (e.g., radioligand concentration and reference Kd). When only IC50 values were available, Kd was estimated using the Cheng–Prusoff equation where the source provided the necessary assay parameters (radioligand concentration and its Kd); the derivation basis was recorded in S2 Data. Bioavailability and receptor-available fraction Bioavailable fractions and sequestration mechanisms were curated through AI-assisted literature searches (GPT-4.5, OpenAI) followed by individual manual verification of each source against the original publication. For each hormone we recorded: (i) the molecular species quantified by routine clinical assays (total hormone or free hormone), (ii) the circulating molecular form considered receptor-available, and (iii) an estimated fraction linking the clinically assayed pool to the receptor-available pool. Known sequestration mechanisms were recorded, including plasma carrier binding, reversible conjugation, and posttranslational modifications; hormones with no significant binding were annotated as “no sequestration.” When the clinical assay measures the receptor-available species directly (e.g., free T3), the bioavailable fraction for that analyte was set to 1.0; a separate column records the free fraction relative to total circulating hormone (e.g., the percent of total T3 that is free) to allow conversion between reporting conventions. Bioavailable fractions and sequestration mechanisms were manually curated from primary literature. This fraction is an operational correction for cross-hormone scaling and does not capture tissue-specific uptake or local metabolism. Circulating half-life curation Hormone half-lives were curated from primary literature with preference for values measured in healthy adults and for the active (and when possible unbound) circulating species. Candidate values were identified via systematic PubMed searches using AI-assisted literature screening (GPT-4.5 and GPT 5.1, OpenAI) with a structured extraction protocol specifying inclusion criteria (human adults, healthy/fasting baseline, IV or infusion pharmacokinetic studies, terminal elimination phase), exclusion criteria (pediatric, pregnancy, disease states, synthetic analogs), and required output fields including the exact location of the extracted value within each source paper. All retrieved values were manually verified against original publications at the reported location before inclusion in S2 Data. Where human data were unavailable, rodent studies were included with clear species annotation. When multiple kinetic phases were reported, we used the terminal (β-phase) half-life as a summary of systemic clearance, and retained notes about the experimental context (endogenous decay, bolus injection, or infusion) and assay format. Reported half-lives were converted to seconds; when studies reported a range or confidence interval, we retained lower and upper bounds and used a central estimate (geometric mean when bounds were multiplicative) for analyses requiring a single value. Primary clearance mechanisms were annotated when reported in the source. Quality control, independence of analysis, and roles Affinity, bioavailability, and half-life subtables were assembled by physician curators (T.K. and S.B.) under supervision of S.F. Each entry was checked for unit consistency, molecular form (total versus free), and alignment between the assay readout and the curated parameter. S.F. reviewed the completed tables, resolved discrepancies across sources, and approved finalized values prior to downstream modeling. The finalized master table was then provided to R.S., who performed the statistical modeling and figure generation independently of the curation process, using the fixed table as input and without iterative tuning of curated parameters. AI-assisted tools (GPT-4, ChatGPT 5.0, OpenAI; Claude, Anthropic) were used during this work in two capacities: (i) preliminary literature search and data extraction during curation of affinity, bioavailability, and half-life datasets, and review of hormone list designations—all AI-retrieved values and classifications were manually verified against original publications before inclusion; and (ii) review of manuscript text for clarity and flow, with all final phrasing decisions made by the authors. Sensitivity analysis DHEAS receptor assignment represents a source of uncertainty in the regression model, as DHEAS-specific receptors were only recently characterized. We assigned DHEAS to the sigma-1 receptor based on cryo-EM evidence for sulfate-selective binding [27, 38], but an alternative DHEAS-specific Gnα11-coupled GPCR with documented function at physiological concentrations was also identified [39]. We restricted our search to receptors for which DHEAS-specific binding or signaling has been demonstrated without requiring desulfation, which identified only these two candidates. To test whether the concentration–affinity correlation (Fig 4) depends on this assignment choice, we substituted a provisional Kd of 500 nM (reflecting the functional affinity range of the Gnα11-GPCR) for the sigma-1 Kd (18 µM) and re-ran the log–log regression on the 56-hormone dataset. R2 decreased from 0.31 to 0.26 (p = 5.1 × 10−5). The concentration–affinity correlation persisted across both DHEAS-specific receptor assignments. Visualization and data analysis We generated distribution maps of both circulating hormone mass and the number of circulating hormone molecules using the Bionic Visualizations (Proteomaps) tool (http://bionic-vis.biologie.uni-greifswald.de/index.php). For the affinity analyses, we fit linear regression models in log10 space relating binding affinity (log10 Kd) to circulating concentration (total or receptor-available). We evaluated extensions that included half-life as a covariate and models allowing slopes and intercepts to vary by hormone class; nested model comparisons used F-tests and information criteria, and uncertainty was summarized with 95% confidence intervals from predictive distributions. Full model specifications, tests, and software libraries are provided in the S1 Appendix. For bioavailability analyses, we used a χ2 test of independence to assess the association between sequestration mechanism and hormone class, with effect size quantified by Cramér’s V. Differences in receptor-available fraction across classes were tested by one-way ANOVA with Tukey HSD post-hoc comparisons. The relationship between receptor-available fraction and circulating half-life among sequestered hormones was assessed by linear regression in log10 space. These tests were performed in Python using scipy.stats. Code used to generate Figs 3–5 and Figs E, H, and I in S1 Appendix is available in the public GitLab repository (tagged release v1.0.0) and archived on Zenodo (DOI: https://doi.org/10.5281/zenodo.20110628) (see Data sharing statement). Precision evaluation and variability assessment To evaluate the precision of our estimates and assess variability in the healthy population, we focused on DHEAS and adiponectin, the two most abundant hormones by copy number and mass. We systematically reviewed literature sources for individuals aged 20–30 years, extracting hormone level distributions. Discrete distributions were constructed from reported individual values, while normal or lognormal distributions were derived from summary statistics provided in the source analyses. Using bootstrapping techniques (1,000 iterations), we determined the median and its 95% confidence interval for each distribution, stratified by hormone and sex. Overall variation was assessed using the 5th and 95th percentiles of the aggregated distributions. Biological variation (CVi and CVg) To contextualize biological variability in circulating hormone concentrations, we queried the EFLM Biological Variation Database [19] (accessed July 30, 2025) for hormones with available standardized within-subject (CVi) and between-subject (CVg) coefficients of variation. For each hormone, we recorded the reported CVi and CVg values and mapped hormones to the biochemical classes used throughout the manuscript. We summarized variability across hormones using medians and report hormone-specific CVi/CVg values in Table D in S1 Appendix. Hormones with pronounced circadian or pulsatile secretion were not modeled with time-resolved profiles; instead, the main analyses represent concentrations using reference-range–anchored summary values (geometric means), with temporal dynamics treated as contributing to dispersion within reported intervals. Comprehensive hormone list compilation To evaluate the comprehensiveness of our 63 clinically-assayed hormones, we compiled an extensive list of human hormones. Sources included textbooks [16–18] and published repositories: the HORDB peptide hormone database [6] (5,729 entries), and the UniProt database [40] (queried on Aug-24–2023 for “hormone” AND “model organism 96 (Homo sapiens)”). We manually curated the resulting 2,267 entries, focusing on endogenous human endocrine hormones. Exclusion criteria are detailed in Figs F and G in S1 Appendix and corresponding tables. For the curated list of primary endocrine signaling molecules, we searched PubMed for serum/blood levels, converted results to pg/ml, and calculated total circulating mass for hormones not in our primary analysis (Table B in S1 Appendix). These results contribute to our error estimate. Supporting information Hormone distribution and circulating abundance estimates (Excel workbook). Workbook used to harmonize adult reference intervals and published concentration data and to derive circulating pool metrics (molarity, total mass, and total molecule counts). Tabs: Hormone_abundance; Hormones_sorted; AU_conversion; LOD; Uniprot_query; HorDB_query; Hormones_comprehensive. (XLSX) Curated receptor affinity, bioavailability, and half-life annotations (Excel workbook). Workbook used for affinity and bioavailability analyses, including the operational hormone–primary receptor mapping, curated Kd values, receptor-available fractions with sequestration mechanism labels, and circulating half-lives. Tabs: Readme; Master_table; Kd; Hormone_affinity_detailed; Bioavailability; Half_life; Copy_of_Hormone_abundance. (XLSX) Statistical Analysis of Receptor Binding Affinity and Circulating Hormone Concentration. Detailed model specifications, statistical testing procedures, and software implementation details for the affinity analyses presented in the main text, including model comparison metrics (Table A in S1 Appendix). Fig A. The distribution of hormone mass in young adult males. Fig B. Circulating hormone mass distribution by secreting tissue/gland in males and females. Fig C. Circulating hormone molarity distribution by secreting tissue/gland. Fig D. Histograms of molecular weight (weighted by molecule count and by total mass). Fig E. Distribution of circulating hormones by molecular weight and abundance in males. Fig F. Distribution of candidate molecules in UniProt database. Fig G. Distribution of candidate molecules in HORDB databases. Fig H. Receptor affinity versus total circulating hormone molarity. Fig I. Sequestration mechanisms by hormone type. Table A. Model comparison metrics for affinity regression models (included in S1 Appendix). Table B. Suggested compilation of human hormones for clinical endocrinology. Table C. Collated adiponectin and DHEAS data from healthy young adult cohorts. Table D. Collated reference change values (RCVs) for 25 hormones [19,34,41–47]. (DOCX) 5 Feb 2025 Dear Dr Fuchs, Thank you for submitting your manuscript entitled "The total mass, copy number, and distribution of hormones in the human bloodstream" for consideration as a Research Article by PLOS Biology. I am writing on behalf of my colleague, Dr. Ines Alvarez-Garcia who is the handling editor for your paper, but who is out of the office at the moment. I am contacting you to let you know that your manuscript has now been evaluated by the PLOS Biology editorial staff as well as by an academic editor with relevant expertise and we would like to send your submission out for external peer review. Please accept our apologies for the time it has taken to send you this initial decision. We had wished to discuss your paper with an expert in this field, and it took us a bit longer than normal to find someone who was available to provide advice. **IMPORTANT: Please note, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire. Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. After your manuscript has passed the checks it will be sent out for review. To provide the metadata for your submission, please Login to Editorial Manager (https://www.editorialmanager.com/pbiology) within two working days, i.e. by Feb 07 2025 11:59PM. If your manuscript has been previously peer-reviewed at another journal, PLOS Biology is willing to work with those reviews in order to avoid re-starting the process. Submission of the previous reviews is entirely optional and our ability to use them effectively will depend on the willingness of the previous journal to confirm the content of the reports and share the reviewer identities. Please note that we reserve the right to invite additional reviewers if we consider that additional/independent reviewers are needed, although we aim to avoid this as far as possible. In our experience, working with previous reviews does save time. If you would like us to consider previous reviewer reports, please edit your cover letter to let us know and include the name of the journal where the work was previously considered and the manuscript ID it was given. In addition, please upload a response to the reviews as a 'Prior Peer Review' file type, which should include the reports in full and a point-by-point reply detailing how you have or plan to address the reviewers' concerns. During the process of completing your manuscript submission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit http://journals.plos.org/plosbiology/s/preprints for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF. Feel free to email us at plosbiology@plos.org if you have any queries relating to your submission. Kind regards, Luke Lucas Smith, PhD Senior Editor PLOS Biology lsmith@plos.org on behalf of Ines Alvarez-Garcia, PhD Senior Editor PLOS Biology ialvarez-garcia@plos.org 27 May 2025 Dear Dr Fuchs, Thank you for your patience while your manuscript entitled "The total mass, copy number, and distribution of hormones in the human bloodstream" was peer-reviewed at PLOS Biology. Please accept also again my sincere apologies for the time it has taken us to provide you with a decision. The manuscript has now been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by three independent reviewers. The reviews are attached below. As you will see, the reviewers find the manuscript interesting and worth pursuing for publication, but they also raise several issues that would need to be addressed. Reviewer 1 thinks that the quantitative data to abundance and binding affinity of receptors of these hormones should be extended and correlated with hormone levels to identify quantitative principles of signal transduction mediated by these hormones. In addition, the reviewer mentions that some of the theoretical questions could be addressed using mathematical models simulating the dynamic response of the ‘reservoir-active’ system to external signals, and makes some suggestions to confirm some of the findings and improve the methods. Reviewer 2 thinks that a brief description of the most frequently found hormones should be provided, and the discussion expanded to add how many hormones follow a circadian rhythm and what approach was taken with cortisol. Reviewer 3 mentions that the scope of the study should be clearly defined and that the claims should be toned down because the entire hormonal landscape is not characterised. This reviewer also notes the need to explain or provide context for the choices to include some precursor molecules and prohormones and not others, discuss hormone half-life or clearance and validate better the total hormonal mass estimates. In light of the reviews, which you will find at the end of this email, we would like to invite you to revise the work to thoroughly address the reviewers' reports. Note that after discussing the reviews with the Academic Editor, we do not think that Reviewer 1's request of addressing some of the theoretical questions using mathematical models is required for publication. Given the extent of revision needed, we cannot make a decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is likely to be sent for further evaluation by all or a subset of the reviewers. In addition to these revisions, you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests shortly. We expect to receive your revised manuscript within 3 months. Please email us (plosbiology@plos.org) if you have any questions or concerns, or would like to request an extension. At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not intend to submit a revision so that we may withdraw it. **IMPORTANT - SUBMITTING YOUR REVISION** Your revisions should address the specific points made by each reviewer. Please submit the following files along with your revised manuscript: 1. A 'Response to Reviewers' file - this should detail your responses to the editorial requests, present a point-by-point response to all of the reviewers' comments, and indicate the changes made to the manuscript. *NOTE: In your point-by-point response to the reviewers, please provide the full context of each review. Do not selectively quote paragraphs or sentences to reply to. The entire set of reviewer comments should be present in full and each specific point should be responded to individually, point by point. You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response. 2. In addition to a clean copy of the manuscript, please also upload a 'track-changes' version of your manuscript that specifies the edits made. This should be uploaded as a "Revised Article with Changes Highlighted" file type. 3. Resubmission Checklist When you are ready to resubmit your revised manuscript, please refer to this resubmission checklist: https://plos.io/Biology_Checklist To submit a revised version of your manuscript, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' where you will find your submission record. Please make sure to read the following important policies and guidelines while preparing your revision and fulfil the editorial requests: a) *PLOS Data Policy* Please note that as a condition of publication PLOS' data policy (http://journals.plos.org/plosbiology/s/data-availability) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). Please also indicate in each figure legend where the data can be found. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5 b) *Published Peer Review* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details: https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/ c) *Blot and Gel Data Policy* Please provide the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements d) *Protocols deposition* To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments. Sincerely, Ines -- Ines Alvarez-Garcia, PhD Senior Editor PLOS Biology ialvarez-garcia@plos.org ------------------------------------ Reviewers' comments Rev. 1: In the manuscript 'The total mass, copy number, and distribution of hormones in the human bloodstream', Sender and colleagues systematically integrated clinical reference ranges and public datasets to quantify the distribution of total mass and copy number of hormones in the human circulation system. Their analyses lead to three main conclusions: (1) Adiponectin and DHEA-S dominate the total abundance of human hormones; (2) abundances of hormones follow the hierarchical structure of the hypothalamic-pituitary axe, except for TRH; (3) active forms of hormones are lower in abundance compared to the reservoir forms. The manuscript is well-written, and the data is open and transparent. I agree with the authors that absolute quantifications are crucial to gain theoretical insights into how biological processes operate, therefore I appreciate the authors' effort in doing so. However, I feel that there is still space to further improve this work from a systems biology perspective (e.g. with mathematical modeling to interpret the rules underlying the hormone abundance data and yield clearly defined theories), as its current form appears to simply list the numbers without converging to a theory about design principles of the endocrine system as they tried to claim in the abstract. Major: 1. The interaction between hormones and receptors is the core of endocrine regulation. Extending the quantitative data to abundance and binding affinity of receptors of these hormones and correlating them with hormone levels could be helpful to reveal quantitative principles of signal transduction mediated by these hormones. For instance, the authors have observed a deviation of TRH abundance from the hierarchical structure of the hypothalamic-pituitary axis, as the abundance of TRH is much higher than TSH. The authors suggest that this deviation might reflect additional regulatory roles of TRH, which is possible, but it could also be a consequence of low binding affinity or high abundance of the receptor of TRH. It would also be helpful to determine whether the high-abundance hormones (e.g. DHEA-S) are associated with high receptor density or low binding affinity. 2. The authors find that for hormones with both inactive reservoir forms and active forms, the abundances of the active forms are much lower than that of the reservoir forms. However, the approach used in this study - direct comparing abundances of the two forms without accounting for the dynamics of interconversion between them - might limit the biological insights one can gain from the data. For instance, why do almost all hormones with both active and inactive forms follow such an abundance pattern? Is the very high abundance of reservoir form indispensable for functions of the hormones, such as robust maintenance of physiological homeostasis and efficient responses to input signals? These important theoretical questions could be addressed by mathematical models simulating the dynamic response of the "reservoir-active" system to external signals. 3. The authors hypothesize that the higher level of TRH in the blood compared to other hypothalamic hormones may imply peripheral functions of TRH that have not been fully recognized. However, there is a lack of direct evidence supporting the hypothesis of its peripheral function. Expression of the TRH receptor (TRHR) in peripheral tissues and cell types can be used as an additional source of data to confirm whether TRH may directly affect peripheral tissues. For example, public gene expression databases can be used to retrieve mRNA and protein expression levels of TRHR in peripheral tissues such as thyroid and cardiovascular systems. 4. The take-home-message of Figure 3 is unclear to me. The authors claim that "clear abundance patterns" emerge when comparing the amount and molecular weight of circulating hormones, but Figure 3 contains a mixture of data points with many different colors (secreting organs) and shapes (hormone types), from which I can only see that the abundance and molecular weight of hormones both vary substantially. For "clear patterns" mentioned above, I was expecting quantitative relationships or constraints coupling the variables visualized, which is difficult to see from the figure. 5. The Methods section is too simplified. For instance, in the subsection "Reference human model and reference conditions", the authors mentioned that a reference human model was used, but it is unclear how this reference model was defined, and what features of this model were used in calculation of the hormone abundances. Was anything other than the body weights of male and female adults used in the calculation? I suggest the authors provide precise mathematical equations to clarify the calculations they have made. Rev. 2: This is an interesting and topical paper, which provides an alternative perspective on the homeostasis and distribution of hormones in the body. My congratulations to the authors on their novel work. My comments are more around the discussion and the need to provide some extra context and emphasise some caveats further. Given the readership of this paper is likely to be broad I think a brief description of the most frequently found hormones might be helpful for interpretation. There is already some discussion around the fact that hormone levels can fluctuate e.g. in pregnancy or during the menstrual cycle. I think this could be expanded further and discuss that many hormones also follow a circadian rhythm. What approach did you take with cortisol for example (the supplementary file has 3 rows for cortisol)? Can the authors please better clarify why they chose to use levels in the cycles where hormones were lowest? At the moment the data refers to healthy young adults (25 years old). Can the authors please include some statements about paediatric and elderly populations? I am not a chemical pathologist but I think a review by one would be warranted prior to publication. Rev. 3: General comments: The authors focus on a scientifically and clinically important and ambitious topic - what are the system-level organizational and functional properties of the human endocrine system. They provide an impressively detailed inventory of dozens of molecules and perform some straightforward analysis in an effort to identify patterns that might yield mechanistic insights. They have organized a substantial amount of information, particularly in the supplement, and this material would be a valuable resource to the biomedical community. The Discussion claims that their study presents a "quantitative framework" that provides "key insights" into "organization and regulation." I see a few interesting hypotheses regarding organization and regulation but no clear validated "key insights." I see a valuable and significant quantitative resource that seems to complement other available resources (like Tietz and biologicalvariation.eu) but no clear framework in terms of tools or new principles that could be readily used by others to provide insights. The scope of the study is not clearly defined or motivated because the Introduction suggests they will characterize "the entire human hormonal landscape," but they study only those 63 hormones with reference intervals available from Tietz or Mayo. They report 124 other hormones that they justify excluding because they represent negligible mass compared to DHEA-S. They thus do not end up characterizing the entire human hormonal landscape. Also, they need to explain or provide context for their choices to include some precursor molecules and prohormones and not others. It seems like those choices are made on the basis of whether a clinical assay exists. It doesn't obviously make sense that all biologically-relevant hormones must also be clinically relevant. The authors also do not discuss hormone half-life or clearance. They mention that some hormones fluctuate but do not provide any detail on fluctuations, which are fundamental to many endocrine functions and would seem very important if the goal is to "characterize the entire human hormonal landscape." The use of existing reference intervals from Tietz/Mayo to estimate typical values is clever but potentially superficial. A comprehensive analysis based on one data source, especially one that the authors did not assemble themselves and whose idiosyncrasies are therefore not known to the authors, would benefit from an assessment of potential bias. The authors validate their estimates of total hormonal mass by comparing studies of DHEA-S and adiponectin, but that's only the first step in much more validation that would need to be done given their goal to characterize the entire landscape. The EFLM database provides some overlapping and complementary information (eg., https://biologicalvariation.eu/search?query=dheas, https://academic.oup.com/clinchem/article/69/1/100/6826991). Specific comments 1. Abstract: "endocrinome" does not seem to be an established term and is not obviously well-defined and seems confusing to use this early. Introducing a new term and saying this study is the "first" to study it is not self-evidently relevant. 2. Methods: What are potential limits and biases of focusing on Mayo reference intervals alone - would comparison with other public resources like EFLM provide some initial guesses? 3. Results a. The finding of about 1M hormones circulating/cell is interesting. b. Comparing abundances in units of mass and mol is interesting but I don't see any "unveil[ed] patterns that potentially correlate with hormone function, glandular origin, and regulatory scheme." Are these potential correlations quantified somewhere? c. I don't see any "clear abundance patterns" in Figure 3, and I'm not sure what the authors' null hypothesis would be for abundance patterns. d. Figure 4 shows an interesting pattern, but is that an unbiased assessment of HPA-related molecules, or have the authors limited to those with similar patterns? What about ADH, oxytocin, and others? e. The authors don't discuss the difference between serum and plasma or whether some of the assays whose reference intervals they analyze may actually be plasma measurements. For understanding physiology, I would think plasma concentrations would be closer to those in vivo and therefore more relevant. f. The authors seem to assume that physiologic importance is strongly determined by abundance: "our analysis captures the vast majority of circulating hormone abundance, providing a reliable quantitative framework for understanding endocrine physiology." If their goal is truly to understand endocrine physiology, I don't think that makes sense. It implies that DHEA-S and adiponectin are the most important molecules to study in order to understand endocrine physiology. 4. Discussion: a. "By clearly delineating inclusion and exclusion criteria": unless the authors mean simply that they relied on the presence of a reference interval, these criteria are not clear. After a few searches to try to understand why, for instance, hepcidin is not included, it looks like its exclusion criterion is "transduction/structural," but I don't understand what that means. b. There is a statement about negligible "production," but have they inferred or discussed any rates of production or half-lives? 4 Mar 2026 Submitted filename: rebuttal_letter_PBP.pdf 8 May 2026 Dear Dr Fuchs, Thank you for your patience while we considered your revised manuscript entitled "The total mass, copy number, and distribution of hormones in the human bloodstream" for publication as a Research Article at PLOS Biology. This revised version of your manuscript has been evaluated by the PLOS Biology editors, the Academic Editor and two of the original reviewers. Based on the reviews (attached below), we are likely to accept this manuscript for publication, provided you satisfactorily address the remaining points raised by Reviewer 3. We do agree with the reviewer that "the first integrative analysis of circulating human hormones…” should be changed to “an integrative (or, a comprehensive, if preferred) analysis of circulating human hormones." Please also make sure to address the data and other policy-related requests stated below my signature. As you address these items, please take this last chance to review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the cover letter that accompanies your revised manuscript. In addition to these revisions, you may need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests shortly. If you do not receive a separate email within a few days, please assume that checks have been completed, and no additional changes are required. We expect to receive your revised manuscript within two weeks. To submit your revision, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' to find your submission record. Your revised submission must include the following: - a cover letter that should detail your responses to any editorial requests, if applicable, and whether changes have been made to the reference list - a Response to Reviewers file that provides a detailed response to the reviewers' comments (if applicable, if not applicable please do not delete your existing 'Response to Reviewers' file.) - a track-changes file indicating any changes that you have made to the manuscript. NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines: https://journals.plos.org/plosbiology/s/supporting-information *Published Peer Review History* Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details: https://plos.org/published-peer-review-history/ *Press* Should you, your institution's press office or the journal office choose to press release your paper, please ensure you have opted out of Early Article Posting on the submission form. We ask that you notify us as soon as possible if you or your institution is planning to press release the article. *Protocols deposition* To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols Please do not hesitate to contact me should you have any questions. Sincerely, Ines -- Ines Alvarez-Garcia, PhD Senior Editor PLOS Biology ialvarez-garcia@plos.org ------------------------------------------------------------------------ DATA POLICY: Thank you for providing the data underlying all the graphs shown in the figures. However, you should indicate clearly in each corresponding figure legend where the data can be found. You can include the link to Zenodo (see our Code policy below) to access the code to generate it. ------------------------------------------------------------------------ CODE POLICY Per journal policy, if you have generated any custom code during the course of this investigation, please make it available without restrictions. Please ensure that the code is sufficiently well documented and reusable, and that your Data Statement in the Editorial Manager submission system accurately describes where your code can be found. More information on our Code Policy, what and how to share can be found here: https://journals.plos.org/plosbiology/s/code-availability Please note that we cannot accept sole deposition of code in GitHub, as this could be changed after publication. However, you can archive this version of your publicly available GitHub code to Zenodo. Once you do this, it will generate a DOI number, which you will need to provide in the Data Accessibility Statement (you are welcome to also provide the GitHub access information). See the process for doing this here: https://docs.github.com/en/repositories/archiving-a-github-repository/referencing-and-citing-content ------------------------------------------------------------------------ Reviewers' comments Rev. 1: The authors have addressed my previous comments. I have no further concerns. Rev. 3: General comments The authors responded thoughtfully and thoroughly to reviewer comments and substantially revised the paper, including new data, analysis, and figures. It is clearly improved. The modestly significant correlation between hormone amount and binding affinity makes sense and might have been anticipated, but I am not aware of clear evidence-based demonstration of this relationship, especially not across as many hormones as is demonstrated in this manuscript. If this relationship is what might be naively expected because it would enhance physiological responsiveness, maybe the more interesting finding is that the empirical correlations might be weaker (especially for peptides and glycoproteins) than one might have expected. Why would some hormones have typical levels far from their Kd? Similarly, is the correlation between receptor-available fraction and half-life what would be naively expected? If so, then maybe what's interesting is that there is, for example, a surprisingly large range of receptor-available fractions (100x) for half-lives between 0.1 and 1 hours. The centrality of adiponectin in the study based on its total mass contrasts sharply with its apparently minimal clinical relevance and seems to distract the reader from the prior two interesting observations. I cannot remember ever seeing an adiponectin level reported in a patient medical record and am not aware that measurement of adiponectin is recommended in a single clinical practice guideline for screening, or disease progression, or treatment response monitoring. Its greatest significance may be as evidence that the quantity of a hormone is not relevant for assessing its importance. In lines 338-340 of the Discussion, the authors rightly note that abundance does not reflect physiological importance, and if they could come up with a better metric of physiologic importance, a future study focusing on the most physiologically important hormones might yield greater insight. Specific comments Abstract and line 48: "the first integrative analysis of circulating human hormones…." Is this study really the first that any reasonable person might call an "integrative analysis of circulating hormones"? Based on what I have read, it's fair to say it's one of the largest. Line 59: The irony is that adiponectin is not "routinely assayed" because it has almost no clinical utility that I am aware of. Figure 4: is there any correlation in panels E and F? I think R^2 should be provided in all panels. Figure 5: Except for glycoproteins, there's not much of a consistent pattern based on type. Discussion (275-286): this examination of the role of tissue mass and the plausible related hypothesis is useful. Discussion (367): "self-reported" race and ethnicity because there is no other kind Throughout: According to Fraser and other laboratory medicine thought leaders, "reference interval" is technically more accurate than "reference range" 25 May 2026 Submitted filename: Response to Reviewers R3.docx 5 Jun 2026 Dear Dr Fuchs, Thank you for the submission of your revised Research Article entitled "The total mass, copy number, and distribution of hormones in the human bloodstream" for publication in PLOS Biology. On behalf of my colleagues and the Academic Editor, James Ferrell, I am delighted to let you know that we can in principle accept your manuscript for publication, provided you address any remaining formatting and reporting issues. These will be detailed in an email you should receive within 2-3 business days from our colleagues in the journal operations team; no action is required from you until then. Please note that we will not be able to formally accept your manuscript and schedule it for publication until you have completed any requested changes. Please take a minute to log into Editorial Manager at http://www.editorialmanager.com/pbiology/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. PRESS We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with biologypress@plos.org. If you have previously opted in to the early version process, we ask that you notify us immediately of any press plans so that we may opt out on your behalf. We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/. Many congratulations and thanks again for choosing PLOS Biology for publication and supporting Open Access publishing. We look forward to publishing your study. Sincerely, Ines -- Ines Alvarez-Garcia, PhD Senior Editor PLOS Biology ialvarez-garcia@plos.org